Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

8 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Increasing Enzyme Mannose-6-Phosphate Levels but Not Miglustat Coadministration Enhances the Efficacy of Enzyme Replacement Therapy in Pompe Mice.
Anding A, Kinton S, Baranowski K, Brezzani A, De Busser H, Dufault MR, Finn P, Keefe K, Tetrault T, Li Y, Qiu W, Raes K, Vitse O, Zhang M, Ziegler R, Sardi SP, Hunter B, George K. Anding A, et al. Among authors: vitse o. J Pharmacol Exp Ther. 2023 Nov;387(2):188-203. doi: 10.1124/jpet.123.001593. Epub 2023 Sep 7. J Pharmacol Exp Ther. 2023. PMID: 37679046
Long-term Safety and Efficacy of Avalglucosidase Alfa in Patients With Late-Onset Pompe Disease.
Dimachkie MM, Barohn RJ, Byrne B, Goker-Alpan O, Kishnani PS, Ladha S, Laforêt P, Mengel KE, Peña LDM, Sacconi S, Straub V, Trivedi J, Van Damme P, van der Ploeg AT, Vissing J, Young P, Haack KA, Foster M, Gilbert JM, Miossec P, Vitse O, Zhou T, Schoser B; NEO-EXT investigators. Dimachkie MM, et al. Among authors: vitse o. Neurology. 2022 Aug 1;99(5):e536-e548. doi: 10.1212/WNL.0000000000200746. Neurology. 2022. PMID: 35618441 Free PMC article.
First-in-human study of the safety, tolerability, pharmacokinetics and pharmacodynamics of single and multiple oral doses of SAR247799, a selective G-protein-biased sphingosine-1 phosphate receptor-1 agonist for endothelial protection.
Bergougnan L, Armani S, Golor G, Tardat A, Vitse O, Hurbin F, Scemama M, Poitiers F, Radzik D, Gaudin C, Hovsepian L, Muslin AJ, Kirkesseli S, Deutsch P, Parkar AA. Bergougnan L, et al. Among authors: vitse o. Br J Clin Pharmacol. 2021 Feb;87(2):598-611. doi: 10.1111/bcp.14422. Epub 2020 Jul 8. Br J Clin Pharmacol. 2021. PMID: 32520410 Free PMC article. Clinical Trial.
Endothelial-protective effects of a G-protein-biased sphingosine-1 phosphate receptor-1 agonist, SAR247799, in type-2 diabetes rats and a randomized placebo-controlled patient trial.
Bergougnan L, Andersen G, Plum-Mörschel L, Evaristi MF, Poirier B, Tardat A, Ermer M, Herbrand T, Arrubla J, Coester HV, Sansone R, Heiss C, Vitse O, Hurbin F, Boiron R, Benain X, Radzik D, Janiak P, Muslin AJ, Hovsepian L, Kirkesseli S, Deutsch P, Parkar AA. Bergougnan L, et al. Among authors: vitse o. Br J Clin Pharmacol. 2021 May;87(5):2303-2320. doi: 10.1111/bcp.14632. Epub 2020 Nov 26. Br J Clin Pharmacol. 2021. PMID: 33125753 Free PMC article. Clinical Trial.
Absorption, Metabolism, and Excretion of [14C]-Tolebrutinib After Oral Administration in Humans, Contribution of the Metabolites to Pharmacological Activity.
Nicolas O, Moliner P, Soubayrol P, Vitse O, Roy S, Cabanis MJ, Turner T, Klieber S, Muccio S, Arabeyre C, Brun P. Nicolas O, et al. Among authors: vitse o. Clin Drug Investig. 2023 Aug;43(8):653-665. doi: 10.1007/s40261-023-01296-1. Epub 2023 Aug 29. Clin Drug Investig. 2023. PMID: 37642857 Free PMC article.
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Alirocumab in Healthy Chinese Subjects: A Randomized, Double-Blind, Placebo-Controlled, Ascending Single-Dose Study.
Li H, Wei Y, Yang Z, Zhang S, Xu X, Shuai M, Vitse O, Wu Y, Baccara-Dinet MT, Zhang Y, Li J. Li H, et al. Among authors: vitse o. Am J Cardiovasc Drugs. 2020 Oct;20(5):489-503. doi: 10.1007/s40256-020-00394-1. Am J Cardiovasc Drugs. 2020. PMID: 32080823 Free PMC article. Clinical Trial.